Active, not recruitingPhase 3NCT04603495
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Pelabresib(drug)
- Enrollment
- 430 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL, Decatur, Illinois, United States
- Franciscan Health/Indiana blood and Marrow Transplantation, Indianapolis, Indiana, United States
- Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
- University of Michigan Medical Center, Ann Arbor, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04603495 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.